复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

未开盘 07-22 16:08:56

22.500

+0.050

+0.22%

最高22.500	最低22.400	成交量19.69万
今开22.450	昨收22.450	日振幅0.45%
总市值122.29亿	流通市值36.77亿	总股本5.43亿
成交额441.75万	换手率0.12%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":22.5,"timestamp":1721635736031,"preClose":22.45,"halted":0,"volume":196900,"delay":0,"floatShares":163428541,"shares":543494853,"eps":1.0753576,"marketStatus":"未开盘","marketStatusCode":0,"change":0.05,"latestTime":"07-22 16:08:56","open":22.45,"high":22.5,"low":22.4,"amount":4417466,"amplitude":0.004454,"askPrice":22.5,"askSize":22800,"bidPrice":22.45,"bidSize":9500,"shortable":0,"etf":0,"ttmEps":1.0700021858606046,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"listingDate":1569340800000,"adjPreClose":22.45,"openAndCloseTimeList":[[1721611800000,1721620800000],[1721624400000,1721635200000]],"volumeRatio":0.475259,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2452556532","title":"18A市值半年考！君圣泰、圣诺医药跌幅近九成，科伦博泰、复宏汉霖、亚盛医药涨幅前三","url":"https://stock-news.laohu8.com/highlight/detail?id=2452556532","media":"医药经济报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452556532?lang=zh_cn&edition=full","pubTime":"2024-07-20 13:31","pubTimestamp":1721453482,"startTime":"0","endTime":"0","summary":"截至7月19日中午，近半年来，总市值跌幅最大的十家企业分别是君圣泰医药、圣诺医药、健世科技、来凯医药、创胜集团、润迈德、康宁杰瑞制药、宜明昂科、德琪医药和兆科眼科。截至公告发布之日，圣诺医药仅赎回了20万美元。截至7月19日中午，科伦博泰、复宏汉霖、亚盛医药、欧康维视生物和东曜药业近半年总市值","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407201333569f6fe90d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407201333569f6fe90d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1515","02257","09939","01875","02511","06855","BK1161","02696","09877","06628","BK1574"],"gpt_icon":0},{"id":"2452875101","title":"复宏汉霖07月17日主力资金流出163万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2452875101","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452875101?lang=zh_cn&edition=full","pubTime":"2024-07-17 16:16","pubTimestamp":1721204171,"startTime":"0","endTime":"0","summary":"07月17日, 复宏汉霖股价跌0.44%，报收22.45元，成交金额1156万元，换手率0.32%，振幅0.67%，量比0.67。复宏汉霖今日主力资金净流出163万元，连续3日净流出，上一交易日主力净流出354万元，今日环比减少53.95%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为80.00%，平均跌幅为3.16%。该股近5个交易日下跌1.10%，主力资金累计净流出353万元；近20日主力资金累计净流出1.73亿元，其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071716164195cd6c3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071716164195cd6c3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2451695727","title":"复宏汉霖07月16日遭主力抛售354万元 环比增加543.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451695727","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451695727?lang=zh_cn&edition=full","pubTime":"2024-07-16 16:16","pubTimestamp":1721117813,"startTime":"0","endTime":"0","summary":"07月16日，复宏汉霖股价收平报22.55元，成交金额1878万元，换手率0.51%，振幅1.33%，量比0.99。复宏汉霖今日主力资金净流出354万元，上一交易日主力净流出55万元，今日环比增加543.64%。该股近5个交易日下跌0.88%，主力资金累计净流出590万元；近20日主力资金累计净流出1.71亿元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161617229f54aaec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161617229f54aaec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2450356913","title":"林利军增持复宏汉霖(02696)111.25万股 每股作价约22.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450356913","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450356913?lang=zh_cn&edition=full","pubTime":"2024-07-11 19:49","pubTimestamp":1720698559,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，7月10日，林利军增持复宏汉霖(02696)111.25万股，每股作价22.8237港元，总金额约为2539.14万港元。增持后最新持股数目约为915.57万股，最新持股比例为5.60%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2450924899","title":"齐鲁狙击罗氏“三驾马车”！HER2生物类似药扎堆，复宏汉霖、正大天晴等谁将突围？","url":"https://stock-news.laohu8.com/highlight/detail?id=2450924899","media":"医药经济报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450924899?lang=zh_cn&edition=full","pubTime":"2024-07-10 19:57","pubTimestamp":1720612642,"startTime":"0","endTime":"0","summary":"在本次齐鲁制药产品获批之前，曲妥珠单抗生物类似药已经有四家企业产品获得上市批准。剑指“三驾马车”齐鲁制药加速产品布局对罗氏“三驾马车”的市场冲击，从贝伐珠单抗开始。本次齐鲁制药获批的曲妥珠单抗，更是对罗氏HER2领域临床治疗重磅大品种展开攻势。其通过特异性结合HER2受体，有效阻断肿瘤细胞增殖信号，显著提升了患者生存率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407102009179f2cfe93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407102009179f2cfe93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2449725368","title":"复宏汉霖07月08日遭主力抛售2445万元 环比增加388.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449725368","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449725368?lang=zh_cn&edition=full","pubTime":"2024-07-08 16:15","pubTimestamp":1720426528,"startTime":"0","endTime":"0","summary":"07月08日, 复宏汉霖股价跌0.65%，报收22.85元，成交金额7361万元，换手率1.97%，振幅1.09%，量比2.78。复宏汉霖今日主力资金净流出2445万元，连续7日净流出，上一交易日主力净流出501万元，今日环比增加388.02%。该股主力净额占比0.65%，港股市场排名2640/2643。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708161538958f1fa8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708161538958f1fa8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2448411298","title":"复宏汉霖07月04日遭主力抛售1943万元 环比增加2984.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448411298","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448411298?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:15","pubTimestamp":1720080950,"startTime":"0","endTime":"0","summary":"07月04日, 复宏汉霖股价跌0.22%，报收22.85元，成交金额2537万元，换手率0.68%，振幅0.87%，量比0.42。复宏汉霖今日主力资金净流出1943万元，连续5日净流出，上一交易日主力净流出63万元，今日环比增加2984.13%。近一年数据显示，该股主力连续5日净流出后，次日下跌概率为66.67%，平均跌幅为1.51%。该股近5个交易日上涨1.11%，主力资金累计净流出5202万元；近20日主力资金累计净流出1.28亿元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041616219f01dd28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041616219f01dd28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2448138582","title":"复宏汉霖(02696.HK)：汉斯状(斯鲁利单抗注射液)联合贝伐珠单抗注射液联合化疗获许可开展一线治","url":"https://stock-news.laohu8.com/highlight/detail?id=2448138582","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448138582?lang=zh_cn&edition=full","pubTime":"2024-07-02 17:02","pubTimestamp":1719910951,"startTime":"0","endTime":"0","summary":"复宏汉霖 (02696.HK)发布公告，近日，向日本药品 医疗器械 综合 机构(PMDA)提交的汉斯状(斯鲁利单抗注射液)联合贝伐珠单抗注射液联合化疗一线治疗转移性结直肠癌(mCRC)的国际多中心3期临床试验通知获得默示许可，根据有关规定，相关临床试验可以在日本开展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021710289ef361b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021710289ef361b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2448187355","title":"复宏汉霖(02696)：汉斯状®(斯鲁利单抗注射液)联合贝伐珠单抗注射液联合化疗于日本获许可开展一线治疗转移性结直肠癌的国际多中心3期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2448187355","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448187355?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:38","pubTimestamp":1719909502,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，向日本药品医疗器械综合机构提交的汉斯状 联合贝伐珠单抗注射液联合化疗一线治疗转移性结直肠癌的国际多中心3期临床试验通知获得默示许可，根据有关规定，相关临床试验可以在日本开展。截至本公告日，汉斯状联合贝伐珠单抗注射液联合化疗一线治疗转移性结直肠癌正于中国内地处于2/3期临床试验中。除已于日本获批外，该国际多中心3期临床研究亦已于中国内地完成首例患者给药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1576","BK1161","BK1141","BK1583","02696"],"gpt_icon":0},{"id":"2448187873","title":"复宏汉霖(02696.HK)创新药“汉斯状”获批在日本开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2448187873","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448187873?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:36","pubTimestamp":1719909360,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 宣布，公司自主开发的创新药物汉斯状近日获国际多中心3期临床试验通知获得默示许可，相关临床试验可以在日本开展。汉斯状主要用作治疗转移性结直肠癌，已于2022年3月获批在内地上市，亦获准在印尼上市，其在于欧盟的上市许可申请亦获得欧洲药品管理局受理，在美国桥接试验正稳步推进中。(vc/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1360828/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03347","BK1576","02696","BK1161","BK1141","06978","159992","BK1583","BK1574"],"gpt_icon":0},{"id":"2448182318","title":"复宏汉霖07月02日主力资金流出811万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448182318","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448182318?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:15","pubTimestamp":1719908118,"startTime":"0","endTime":"0","summary":"07月02日, 复宏汉霖股价涨0.22%，报收22.90元，成交金额2694万元，换手率0.73%，振幅1.31%，量比0.24。复宏汉霖今日主力资金净流出811万元，连续3日净流出，上一交易日主力净流出2026万元，今日环比减少59.97%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为75.00%，平均跌幅为4.00%。该股近5个交易日上涨21.55%，主力资金累计净流出1.08亿元；近20日主力资金累计净流出1.08亿元，其中净流出天数为4日。该股主力净额占比0.22%，港股市场排名2627/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702161528956522ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702161528956522ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2448678239","title":"复宏汉霖(02696)：毛应波获委任为公司副总裁兼首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2448678239","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448678239?lang=zh_cn&edition=full","pubTime":"2024-07-01 18:04","pubTimestamp":1719828260,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，基于公司首席执行官朱俊先生的提名，毛应波先生自2024年7月1日起获委任为公司副总裁兼首席财务官，向首席执行官朱先生汇报。朱先生自同日起不再担任首席财务官职务，但将继续担任公司执行董事、首席执行官等职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2447964436","title":"创新药企复宏汉霖消亡史","url":"https://stock-news.laohu8.com/highlight/detail?id=2447964436","media":"经济观察报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447964436?lang=zh_cn&edition=full","pubTime":"2024-06-29 16:59","pubTimestamp":1719651548,"startTime":"0","endTime":"0","summary":"经济观察网 记者 瞿依贤 复宏汉霖，这家港股18A创新药企中首家实现盈利的公司，即将成为历史。6月24日，停牌一个月后的复宏汉霖（02696.HK）和其控股股东复星医药（600196.SH/02196.HK）联合发了一则公告：复星医药旗下控股子公司复星新药拟以吸收合并方式对复宏汉霖私有化，交易价格不超过54.07亿港元。在吸收合并交易前，...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/Oy-zuiMTJnZxBibJKsbdBv5scrcOUI6I3Ail5ST9inddUAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Oy-zuiMTJnZxBibJKsbdBv5scrcOUI6I3Ail5ST9inddUAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240629A061QR00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240629A061QR00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["06978","BK1161","BK1574","02696"],"gpt_icon":0},{"id":"2446557334","title":"复宏汉霖(02696)自研达雷妥尤单抗生物类似药HLX15一期临床研究已完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2446557334","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446557334?lang=zh_cn&edition=full","pubTime":"2024-06-28 16:54","pubTimestamp":1719564862,"startTime":"0","endTime":"0","summary":"金吾财讯 | 上海复宏汉霖 宣布，近日，一项公司自主研发的达雷妥尤单抗生物类似药HLX15在中国男性健康受试者中开展的1期临床研究已成功完成。研究结果表明，HLX15与不同来源的达雷妥尤单抗的药代动力学特征相似，安全性和免疫原性均可比。HLX15是公司自主研发的达雷妥尤单抗生物类似药，拟用于多发性骨髓瘤的治疗。研究结果表明，HLX15与达雷妥尤单抗注射液高度相似。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939537","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2446571578","title":"复宏汉霖(02696.HK)治疗多发性骨髓瘤药完成1期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2446571578","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446571578?lang=zh_cn&edition=full","pubTime":"2024-06-28 16:35","pubTimestamp":1719563700,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 公布，近日公司自主研发的达雷妥尤单抗生物类似药HLX15在中国男性健康受试者中开展的1期临床研究已成功完成。研究结果表明，HLX15与不同来源的达雷妥尤单抗的药代动力学特征相似，安全性和免疫原性均可比。该研究达到了所有预设的研究终点。HLX15是公司自主研发的达雷妥尤单抗生物类似药，拟用于多发性骨髓瘤的治疗。(ha/k)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1360174/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2446584573","title":"复宏汉霖(02696)：达雷妥尤单抗生物类似药HLX15(重组抗CD38全人单克隆抗体注射液)成功完成1期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2446584573","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446584573?lang=zh_cn&edition=full","pubTime":"2024-06-28 16:34","pubTimestamp":1719563695,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，一项公司自主研发的达雷妥尤单抗生物类似药HLX15在中国男性健康受试者中开展的1期临床研究已成功完成。研究结果表明，HLX15与不同来源的达雷妥尤单抗的药代动力学特征相似，安全性和免疫原性均可比。根据《生物类似药研发与评价技术指导原则(试行)》，公司对HLX15与原研药达雷妥尤单抗注射液进行了药学和体内外药理学全面的头对头比较研究。研究结果表明，HLX15与达雷妥尤单抗注射液高度相似。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2446520139","title":"复宏汉霖06月28日遭主力抛售2026万元 环比增加459.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446520139","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446520139?lang=zh_cn&edition=full","pubTime":"2024-06-28 16:15","pubTimestamp":1719562544,"startTime":"0","endTime":"0","summary":"06月28日, 复宏汉霖股价跌0.65%，报收22.85元，成交金额4147万元，换手率1.11%，振幅1.52%，量比0.38。复宏汉霖今日主力资金净流出2026万元，上一交易日主力净流出362万元，今日环比增加459.67%。该股近5个交易日上涨21.55%，主力资金累计净流出9976万元；近20日主力资金累计净流出9976万元，其中净流出天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062816160395e1d247&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062816160395e1d247&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2446099521","title":"复星医药在估值底部整合全球资产 开启下一轮周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2446099521","media":"蓝鲸财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446099521?lang=zh_cn&edition=full","pubTime":"2024-06-28 15:32","pubTimestamp":1719559920,"startTime":"0","endTime":"0","summary":"通过私有化复宏汉霖，复星医药或能够进一步整合调整其创新药领域的产业链版图，拓宽其在全球医药行业的市场竞争力。而在经历了2023年新冠疫情产品收入大幅下降的影响之后，复星医药已经逐渐走出阴霾，今年更是其资产调仓的好时机。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062815350295e1a849&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062815350295e1a849&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600196","BK0028","BK0175","BK0060","BK0196","BK0239","BK0012","BK0183","BK0188","02696","BK0187","BK0096","02196"],"gpt_icon":0},{"id":"2446519492","title":"【特约大V】郭家耀：投资者继续关注外围息口去向及内地政策消息 料指数反复下试17,500点支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2446519492","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446519492?lang=zh_cn&edition=full","pubTime":"2024-06-28 09:30","pubTimestamp":1719538257,"startTime":"0","endTime":"0","summary":"内地股市昨日下跌，沪综指低开低走，收市下跌0.9%，沪深两市成交额进一步缩减。港股表现向下，人民币走势持续偏弱，大市失守18,000点水平，其后跌幅逐步扩大，整体成交亦略为增加。投资者继续关注外围息口去向及内地政策消息，预料指数反复下试17,500点支持，上方阻力在18,200点水平。复星医药指出，合并对复宏汉霖股东在艰难的资本市场环境下，藉注销价可提供具有吸引力的退出溢价。复星医药目前持有复宏汉霖约65.23%股权。","market":"us","thumbnail":"https://static.szfiu.com/news/20200915/OWU3Mzg4NGIxZWQxMTIwMDAxODc5MDA0MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/OWU3Mzg4NGIxZWQxMTIwMDAxODc5MDA0MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939481","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1593","BK1161","BK1515","02696","02196"],"gpt_icon":0},{"id":"2446216903","title":"复宏汉霖私有化，一场大股东间的“相互成全”｜焦点分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2446216903","media":"36氪","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446216903?lang=zh_cn&edition=full","pubTime":"2024-06-27 09:07","pubTimestamp":1719450424,"startTime":"0","endTime":"0","summary":"文｜胡香赟编辑｜海若镜停牌一月后，18A企业复宏汉霖的私有化传言正式被验证。6月24日，复星医药晚间公告称，将通过吸收合并的方式私有化子公司复宏汉霖。后者于2019年登陆港交所，是中国生物医药fast follow时代的典型产物。今年5月底，受“一项构成内幕消息的收购及合并守则公告”影响停牌前，复宏汉霖股价报18.84港元/股...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OXw31UrImnG9XxNfwmZgOM-dHKdKad9LQWJi2mSXWmeDgAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OXw31UrImnG9XxNfwmZgOM-dHKdKad9LQWJi2mSXWmeDgAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240627A01L7W00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240627A01L7W00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["02696","BK1161"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":0.1916},{"period":"3month","weight":0.5148},{"period":"6month","weight":0.5788},{"period":"1year","weight":0.8047},{"period":"ytd","weight":0.6151}],"compareEarnings":[{"period":"1week","weight":-0.0479},{"period":"1month","weight":-0.0549},{"period":"3month","weight":0.0736},{"period":"6month","weight":0.1378},{"period":"1year","weight":-0.0798},{"period":"ytd","weight":0.0217}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。该公司的主要产品包括利妥昔单抗注射液HLX01（汉利康）、赫赛汀（曲妥珠单抗）生物类似药HLX02、修美乐（阿达木单抗）生物类似药HLX03和安维汀（贝伐珠单抗）生物类似药HLX04以及候选生物创新药，包括HLX06（一种新型VEGFR2抑制剂）、HLX07（一种EGFR抑制剂）、HLX10（一种新型PD-1抑制剂）、HLX20（一种新型PD-L1抑制剂）及HLX22（一种新型HER2抑制剂）等。该公司还提供相关技术服务。该公司主要在中国境内和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.004462},{"month":2,"riseRate":0.6,"avgChangeRate":0.003175},{"month":3,"riseRate":0.4,"avgChangeRate":-0.070667},{"month":4,"riseRate":0.8,"avgChangeRate":0.127521},{"month":5,"riseRate":0.4,"avgChangeRate":-0.068918},{"month":6,"riseRate":0.6,"avgChangeRate":0.1049},{"month":7,"riseRate":0.4,"avgChangeRate":0.019075},{"month":8,"riseRate":0.25,"avgChangeRate":-0.071804},{"month":9,"riseRate":0,"avgChangeRate":-0.17846},{"month":10,"riseRate":0.4,"avgChangeRate":-0.013739},{"month":11,"riseRate":0.8,"avgChangeRate":0.086734},{"month":12,"riseRate":0.8,"avgChangeRate":-0.01905}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}